$BHVN

Biohaven Ltd

  • NEW YORK STOCK EXCHANGE INC.
  • Health Technology
  • Pharmaceuticals: Major
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$16.82 ▲0.478%

Extented Hours

VOLUME

868,287

DAY RANGE

15.95 - 17.86

52 WEEK

5.54 - 17.86

Join Discuss about BHVN with like-minded investors

profile
@dros #droscrew
recently

RECAP 8/22 Unusual Calls: $NKLA Sep02 6 C $SJT Jan 15 C $AMZN Sep 162.5 C $PAGP Sep 12 C $STNE Jan 13 C $CLAR Sep 30 C $BHVN Jan 150 C $AAPL Sep 185 C $C Oct 57.5 C $CNX Oct 20 C $BAC Jan 40 C $BAC Oct 38 C $FIS Oct 110 C

73 Replies 13 👍 13 🔥

SC
@Schmidy23 #droscrew
recently

pfe scooping bhvn not the worst play/sign for bio

101 Replies 15 👍 12 🔥

profile
@CarlosH-carvan #ivtrades
recently

$BHVN 170C Jul

61 Replies 10 👍 12 🔥

profile
@HeyShoe #droscrew
recently

RECAP 1/13 Chatter: $TKAT - China NFT $EZPQ CEO resigns $QS + moving beyond EVs $DNB - FTC $XLNX $AMD + SAMR $AUPH $AMLX $BHVN + $BIIB $PFE $BNTX $MRNA - SCOTUS Biden Vaccine ruling

73 Replies 9 👍 14 🔥

profile
@ivtrades-Chris #ivtrades
recently

1500 $BHVN Sep21 125 Calls trade $7.30 (FT Theo=5.96) ASKSIDE AMEX IV=65.3% +11.8 FLOOR - OPENING Post-Earnings Vol=2003, OI=14,

51 Replies 9 👍 10 🔥

profile
@HeyShoe #droscrew
recently

RECAP 6/18 Chatter $BHVN Dealreporter $NIO + China EV sales $CODX + Sars Saliva test $WKHS + Trademark $PYPL + price increase

72 Replies 12 👍 14 🔥

profile
@dros #droscrew
recently

2450 $BHVN OCT2021 $100 Cs trade 11.5

61 Replies 11 👍 8 🔥

profile
@dros #droscrew
recently

2450 $BHVN OCT2021 $100 Cs trade 11.5

101 Replies 10 👍 9 🔥

profile
@ivtrades-Chris #ivtrades
recently

2450 $BHVN Oct21 100 Calls trade $11.50 (FT Theo=9.94) ASKSIDE AMEX 13:57:34 IV=58.5% +7.7 CROSS - OPENING Vol=2459, OI=339

59 Replies 10 👍 8 🔥

profile
@DarkPoolAlgo #Dark Pool Charts
recently

/*============================================= = FRIDAY - 05/28221 Morning = =============================================*/ U.S. futures adding to yesterday gains, looking higher across the board ahead of another busy morning of economic data, as the S&P 500 look to close out May with its 4th straight monthly advance. Improving sentiment about the economic recovery, an accommodative Fed, improving earnings results this past quarter as companies come out of the pandemic and bullish market momentum has fueled the market rally. Reports yesterday indicated that President Joe Biden will unveil a budget of $6 trillion in the coming fiscal year, which help boosted equities, particularly those that would benefit most from increased federal spending. SmallCap stock have been the biggest beneficiaries this week as the Russell 2000 index comes into the trading day with a 2.6% advance this week. Still absolutely no concern or fear in the market with the CBOE Volatility index (VIX) holding around 16.75 (down from levels around 27 just 2-weeks ago). In Asian markets, The Nikkei Index jumped 600 points to 29,149, the Shanghai Index dipped -8 points to 3,600 and the Hang Seng Index inched higher 11 points to 29,124. In Europe, the German DAX is up 75 points to 15,480, while the FTSE 100 is up a few points to 7,025. Market Closing Prices Yesterday The S&P 500 Index edged higher 4.89 points, or 0.12%, to 4,200.88 The Dow Jones Industrial Average rose 141.59 points, or 0.41%, to 34,464.64 The Nasdaq Composite dipped -1.72 points, or 0.01%, to 13,736.28 The Russell 2000 Index advanced 23.80 points, or 1.06% to 2,273.07 Events Calendar for Today 8:30 AM EST Personal Income MoM for April…est. -14.1% 8:30 AM EST Personal Spending MoM for April… 8:30 AM EST PCE Price Index MoM for April 8:30 AM EST PCE Prices Index YoY for April 8:30 AM EST Core PCE Price Index MoM for April…est. 0.6% 8:30 AM EST Core PCE Prices Index YoY for April…est. 2.9% 8:30 AM EST Advance Goods Trade Balance for April…prior -$90.6B 9:45 AM EST Chicago PMI for May…est. 68.0 10:00 AM EST University of Michigan Sentiment, May-F…est. 82.9 1:00 PM EST Baker Hughes Weekly rig count data Earnings Calendar: Earnings Before the Open: BIG, CAL, HIBB Macro Up/Down Last Nymex 0.25 67.10 Brent 0.17 69.63 Gold -2.75 1,893.75 EUR/USD -0.0006 1.2189 JPY/USD 0.06 109.87 10-Year Note +0.001 1.611% World News The U.S. Senate on Thursday advanced a sweeping package of legislation intended to boost the country’s ability to compete with Chinese technology, as Congress increasingly seeks to take a tough line against Beijing. Senators voted 68-30 to end debate on the $250 billion U.S. Innovation and Competition Act of 2021 Sector News Breakdown Consumer Big Lots ($BIG) Q1 EPS $2.62 vs. est. $1.69; Q1 revs $1.63B vs. est. $1.53B; Q1 comp sales rose 11.3%; sees Q2 EPS in the range of $1.00 to $1.15 (est. $1.04), based on a low double digit comparable sales decline which equates to a two-year stacked comparable sales increase of around 20% Hibbett Sports (HIBB) Q1 EPS $5.00 vs. est. $2.77; Q1 revs $506.9M vs. est. $412.92M; Q1 comp sales jumped 87.3%; raises FY22 EPS view to $8.50-$9.00 from $5.00-$5.50 (est. $5.80); says year comp sales vs. the prior year are expected to be in a range from positive high-single digits to positive low-double digits, up from previous guidance of negative low-single digits to positive low-single digits Costco ($COST) Q3 EPS $2.75 vs. est. $2.34; Q3 revs $44.38B vs. est. $43.64B; Q3 total comp sales ex-fuel +15.1% vs. est. 12.7%; comparable sales including gas up 20.6% vs. est. 16%; Q3 comparable e-commerce sales up 41.2%; Q3 Membership fees $901 million, +11% YoY Gap Stores ($GPS) Q1 adj EPS 48c vs. est. loss (5c); Q1 revs $4B vs. est. $3.44B; expects fiscal 2021 net sales to grow in the low-to-mid 20% range from a year ago, compared with its prior projection of mid-to-high teens (est. 17.85); raises year EPS view to $1.55-$1.70 from its prior forecast of $1.20-$1.35; Q1 Gap comp sales up 28% YoY, old Navy comps 27% Guess Inc. ($GES) Q1 adj EPS 21c vs. est. loss (19c); Q1 revs $520M vs. est. $497.44M; says not providing detailed guidance for q2 or full fiscal year; sees Q2 revs to be down mid-single digits versus Q2 of fiscal 2020; said Q1 Americas retail comp sales including e-commerce increased 6% in U.S. dollars and 5% in constant currency; says for FY22 revs expect revenues to be down mid-single digits versus fiscal 2020 Ollie’s Bargain ($OLLI) Q1 EPS 80c vs. est. 63c; Q1 revs $452.5M vs. est. $422.07M; Q1 comp store sales increased 18.8% vs. est. 9.6%; opened 11 new stores, including two relocations, ending the quarter with 397 stores in 25 states, a year-over-year increase in store count of 10.3%; still not providing guidance for the year O’Reilly Automotive ($ORLY) increases buyback authorization by $1.5B Tesla ($TSLA) Model 3 loses CR top pick status and IIHS safety award after dropping features – Consumer Reports Ulta Beauty ($ULTA) Q1 EPS $4.10 vs. est. $1.92; Q1 sales $1.9B vs. est. $1.64B; Q1 comp sales surged 65.9% driven by a 52.5% increase in transactions and an 8.8% increase in average ticket; raises year outlook; boosts FY21 EPS view to $11.50-$11.95 from $8.85-$9.30 (est. $9.85) and raises FY21 revenue view to $7.7B-$7.8B from $7.2B-$7.3B (est. $7.41B) Energy, Industrials and Materials Boeing Co. ($BA) has halted deliveries of its 787 Dreamliners, adding fresh delays for customers following a recent five-month suspension in handing over the aircraft due to production problems, the WSJ reported. Federal air-safety regulators have requested more information about Boeing’s proposed solution to address the previously identified quality lapses https://on.wsj.com/3fQaDm7 Jacobs ($J) was awarded the Idaho Cleanup Project (ICP) at the Idaho National Laboratory (INL), and estimates the contract value at $6.4 billion, to be awarded over a 10-year period. LyondellBasell ($LYB) boosts quarterly dividend by 7.6% to $1.13 per share Titan Machinery ($TITN) upgraded to Overweight from Equal Weight at Stephens and raise tgt to $40 from $26 Healthcare Biohaven Pharmaceutical Holding Company Ltd. (BHVN) said the FDA has approved NURTEC(R) ODT (rimegepant 75 mg) for the preventive treatment of migraine Bristol Myers ($BMY) said the FDA approves its Zeposia® (ozanimod), an oral treatment for adults with moderately to severely active ulcerative colitis1 Centessa Pharma ($CNTA)5M share IPO priced at $20.00 Technology, Media & Telecom Autodesk ($ADSK) Q1 non-Gaap EPS $1.03 vs. est. $0.94; Q1 revs $989M vs. est. $965.2M; Total billings increased 10 percent to $974M; remain on track to achieve our fy23 financial goals; raising our fy22 revenue guidance to reflect a partial year contribution from acquisitions; qtrly subscription plan revenue was $948 mln, an increase of 18% as reported Box Inc. ($BOX) Q1 adj EPS 18c vs. est. 17c; Q1 revs $202.4M vs. est. $200.48M; Q1 Billings were $159.4M, up 24% YoY; mixed guidance as cuts FY22 adjusted EPS view to 71c-76c from 76c-81c (est. 80c) though boosts FY22 revs view to $845M-$853M from $840M-$848M (est. $844.71M) Dell Inc. ($DELL) Q1 adj EPS $2.13 vs. est. $1.61; Q1 revs $24.5B vs. est. $23.4B; revised debt paydown target for fy22 to at least $16b upon completion of spin-off of VMW; Q1 Product revenue was $18 billion, up 12%; services revenue was $6.5 billion, up 10%; Gross margin was flat with a year ago, at 31%; noted that cash flow from operations over the past 12 months was a record $14.4 billion; Dell’s Client Solutions Group (PC business), had revenue of $13.3 billion, up 20%, operating income for the group was $1.1 billion, up 84%. Domo Inc. ($DOMO) 1Q adj EPS ($0.26) vs. est. ($0.43) on revs $60.1Mm vs. est. $57.5Mm; guides 2Q revs $60-61Mm vs. est. $59.7Mm, sees 2Q adj EPS loss $0.35-0.39 vs. est. loss $0.40; guides FY revs $246-252Mm vs. est. $246Mm, sees FY adj EPS loss $1.33-1.41 vs. est. loss $1.54 HP Inc. ($HPQ) Q2 EPS 93c vs. est. 89c; Q2 revs 15.88B vs. est. $15B; net cash provided by operating activities in Q2 was $1.4B; Printing revenue rose 28% in the most recent quarter, driven by a 77% increase in consumer revenue; raised profit projections for the year, saying it now expects $3.24-$3.34 a share, or $3.40-$3.50 as adjusted, vs. previously projected $2.98-$3.08, or $3.15-$3.25 adj Lions Gate ($LGF) Q4 adj EPS 0c vs. est. loss (31c); Q4 revs $876.4M vs. est. $809.31M; global streaming subscribers increased 69% year over year to 16.7 mln at qtr end; says enter FY22 with full content pipelines and with STARZ projected to achieve even better net subscriber adds domestically and internationally than in FY21 com ($CRM) Q1 adj EPS $1.21 vs. est. $0.88; Q1 revs $5.96B vs. est. $5.89B; said raising our revenue guidance for this fiscal year by $250 million to approximately $26 billion and non-GAAP operating margin to 18%; sees Q2 EPS 91c-92c vs. est. 86c; sees Q2 revs $6.22B-$6.23B vs. est. $6.15B; raises FY22 adjusted EPS view to $3.79-$3.81 from $3.39-$3.41 Veeva Systems ($VEEV) Q1 adj EPS 91c vs. est. 78c; Q1 revs $433.6M vs. est. $410.03M; guides s Q2 adj EPS 85c-86c vs. est. 80c; sees Q2 revs $450M-$452M vs. est. $427.46M; sees FY22 adj EPS $3.49 vs. est. $3.24; sees FY22 revs $1.815B-$1.825B vs. est. $1.76B VMWare ($VMW) Q1 EPS $1.76 vs. est. $1.73; Q1 revs $2.9BB vs. est. $2.98B; Q1 combination of subscription and SaaS and license revenue was $1.39B, an increase of 12% YoY; Subscription and SaaS revenue for the first quarter was $741M, an increase of 29% year-over-year; boosts FY22 revenue view to $12.8B from $12.7B Yext Inc. ($YEXT) Q1 EPS loss (2c) vs. est. loss (6c); Q1 revs $92.0M vs. est. $88.55M; sees Q2 non-GAAP EPS loss of (9c)-(7c) vs. est. loss (5c); sees Q2 revs $94M-$96M vs. est. $92.96M; Q1 Total Customer Count Increased 22% Year-over-Year to Over 2,500; Q1 ARR rose 14% YoY to 4370M; raises FY22 revenue view to $381M-$386M from $375M-$380M (est. $377.75M)

85 Replies 14 👍 15 🔥

profile
@dros #droscrew
recently

779 $BHVN 18DEC20 $110 Cs bought 2.74

107 Replies 14 👍 13 🔥

profile
@dros #droscrew
recently

779 $BHVN 18DEC20 $110 Cs bought 2.74

74 Replies 10 👍 9 🔥

DA
@daves #droscrew
recently

Notable earnings before Monday's open ALE, BCOR, BHVN, BIP, BKI, BTU, CARS, CGC, CNNE, EBIX, GOGO, HL, HWM, ICPT, MCD, PLUG, RDNT, RETA, TGNA

41 Replies 12 👍 15 🔥

Key Metrics

Market Cap

1.14 B

Beta

0

Avg. Volume

899.15 K

Shares Outstanding

68.16 M

Yield

0%

Public Float

0

Next Earnings Date

Next Dividend Date

Company Information

Biohaven Pharmaceutical Holding Company Ltd. is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's neuroinnovation portfolio includes FDA-approved NURTEC ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, Alzheimer's disease, and spinocerebellar ataxia; and MPO inhibition for multiple system atrophy and amyotrophic lateral sclerosis.

Website:

HQ: ,

Related News